Supplementary Table 2. Vaccine Effectiveness of Bivalent Compared with Effectiveness of Original Monovalent Vaccination Against All-cause Thromboembolic Events Among Immunocompetent Medicare Beneficiaries Aged ≥65 Years and Beneficiaries Aged ≥18 Years with End Stage Renal Disease Receiving Dialysis Without Additional Immunocompromising Conditions, by Age Group and Time Since Vaccination — United States, September 2022–March 2023
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates
...

to

...
Document Data
Library
People
Clear All
...
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

Supplementary Table 2. Vaccine Effectiveness of Bivalent Compared with Effectiveness of Original Monovalent Vaccination Against All-cause Thromboembolic Events Among Immunocompetent Medicare Beneficiaries Aged ≥65 Years and Beneficiaries Aged ≥18 Years with End Stage Renal Disease Receiving Dialysis Without Additional Immunocompromising Conditions, by Age Group and Time Since Vaccination — United States, September 2022–March 2023



English

Details:

  • Alternative Title:
    Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023: Supplementary Table 2. Vaccine Effectiveness of Bivalent Compared with Effectiveness of Original Monovalent Vaccination Against All-cause Thromboembolic Events Among Immunocompetent Medicare Beneficiaries Aged ≥65 Years and Beneficiaries Aged ≥18 Years with End Stage Renal Disease Receiving Dialysis Without Additional Immunocompromising Conditions, by Age Group and Time Since Vaccination — United States, September 2022–March 2023
  • Source:
  • Series:
  • ISSN:
    0149-2195 (print);1545-861X (digital);
  • Document Type:
  • Genre:
  • Pages in Document:
    2 pdf pages
  • Volume:
    73
  • Issue:
    1
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:
    Filetype[PDF-166.48 KB]

Related Documents

You May Also Like

Checkout today's featured content at stacks.cdc.gov